WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) — Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a complicated clinical-stage biotechnology corporate thinking about raising the following generation of weight problems care, lately introduced the pricing of its preliminary public providing of 39,062,500 stocks of its commonplace inventory at a worth to the general public of $16.00 consistent with proportion. The entire stocks of commonplace inventory are being presented by way of Kailera. The gross proceeds from the providing, sooner than deducting underwriting reductions and commissions and providing bills payable by way of Kailera, are anticipated to be $625.0 million, except any workout of the underwriters’ possibility to buy further stocks. Kailera’s commonplace inventory is anticipated to start buying and selling at the Nasdaq International Make a choice Marketplace beneath the ticker image “KLRA” on April 17, 2026. The providing is anticipated to near on April 20, 2026, matter to the pleasure of commonplace ultimate prerequisites. As well as, Kailera has granted the underwriters a 30-day possibility to buy as much as an extra 5,859,375 stocks of commonplace inventory on the preliminary public providing worth much less underwriting reductions and commissions.
J.P. Morgan, Jefferies, Leerink Companions, TD Cowen and Evercore ISI are appearing as joint book-running managers for the providing. William Blair is appearing as lead supervisor for the providing.
This press unlock does no longer represent an be offering to promote or a solicitation of an be offering to shop for those securities, nor shall there be any be offering or sale of those securities in any state or jurisdiction through which such be offering, solicitation or sale can be illegal previous to registration or qualification beneath the securities regulations of this kind of state or jurisdiction.
